As overexpression of CARMA3 proteins induces robust NF-kB activation [3], [4], CARMA3 and NF-kB may serve as potential companion drug targets along with EGFR in EGFR-mutant lung cancer. This evidence concerns the gene NFKB1 and lung carcinoma.